Caution, this is an AI generated summary based on literature. This may have errors, see here for more.
Please share your feedback with us.
SNORD116-4: SNORD116-4 is a snoRNA that is upregulated in post-therapeutic LACC samples compared to pre-therapeutic LACC samples, along with other snoRNAs such as SNORD116-2, SNORD107, SNORD61, SNORD112, and SNORD109A [PMC6900565]. The levels of SNORD116s not included in any sno-lncRNAs were assessed using primer pairs designed specifically for SNORD116-4 [PMC9896466]. High expression of SNORD116-4 is associated with poor prognosis in ovarian cancer patients [PMC6686521]. However, it was not highly expressed in ovarian cancer patients with OS [PMC6686521]. The expression of SNORD89 and SNORD116-4 predicts poor prognosis in ovarian cancer patients [PMC6686521]. In stage III ovarian cancer patients, high expression of SNORD116-4 is associated with poor prognosis, while in stage IV patients it is associated with better prognosis [PMC6686521]. However, the high expression of SNORD116-4 does not significantly affect the 5-year survival rate of stage III and IV ovarian cancer patients [PMC6686521].
Genome locations
Gene Ontology annotations
Ancestor Chart
Loading ontology ancestors...
Failed to load QuickGO Ancestor chart
Sequence
Sequence features are shown above as colored rectangles.
Zoom in and click to view details, or
Reset